Blockade of proliferation and tumor necrosis factor-α production occurring during mixed lymphocyte reaction by interferon-γ-specific natural antibodies contained in intravenous immunoglobulins

Transplantation

Volumn 62, Issue 9, 1996, Pages 1292-1296

  Toungouz, Michel ^a,b   Denys, Chantal ^a   Dupont, Etienne ^a  

^a ERASME HOSPITAL   (Belgium)

^b FUND FOR SCIENTIFIC RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HLA ANTIGEN; IMMUNOGLOBULIN; IVEGAM; MACROPHAGE ACTIVATING FACTOR; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; RECOMBINANT GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; T LYMPHOCYTE;

ANTIBODIES; CELL DIVISION; GRAFT REJECTION; GRAFT VS HOST DISEASE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; ORGAN TRANSPLANTATION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030477069     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199611150-00020     Document Type: Article

References (36)

1. Kaveri SV, Dietrich G, Hurez V, Kazatchkine MD. Intravenous immunoglobulins (IVIg) in the treatment of autoimmune disease. Clin Exp Immunol 1991; 86: 192.
2. Sullivan KM, Kopecky KJ, Jocom J, et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 1990; 323: 705.
3. Riggio RR, Suthantiran M, Cheigh JS, et al. Enhanced graft survival with retroplacental source γ-globulin. Transplantation 1982; 33: 636.
4. Dwyer JM. Manipulating the immune system with immune globulin. N Engl J Med 1992; 326: 107.
5. Amran D, Renz H, Lack G, Bradley K, Gelfand EW. Suppression of cytokine-dependent human T-cell proliferation by intravenous immunoglobulin. Clin Immunol Immunopathol 1994; 73: 180.
6. Andersson UG, Björk L, Skansén-Saphir U, Andersson JP. Down-regulation of cytokine production and interleukin-2 receptor by pooled human IgG. Immunology 1993; 79: 211.
7. Klaesson S, Ringden O, Markling L, Remberger M, Lundkvist I. Immune modulatory effects of immunoglobulins on cell-mediated immune responses in vitro. Scand J Immunol 1993; 38: 477.
8. Kawada K, Terasaki PI. Evidence for immunosuppression by high-dose gammaglobulin. Exp Hematol 1987; 15: 133.
9. Van Schaik IN, Lundkvist I, Vermeulen M, Brand A. Polyvalent immunoglobulin for intravenous use interferes with cell proliferation in vitro. J Clin Immunol 1992; 12: 325.
10. Glotz D, Haymann J-P, Sansonettis N, et al. Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIg): a potential tool for transplantation of immunized patients. Transplantation 1993; 56: 335.
11. Tyan DB, Li VA, Czer L, Trento A, Jordan SC. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with histoincompatible organ. Transplantation 1994; 57: 553.
12. Suciu-Foca N, Reed E, Rohowsky C, Kung P, King DW. Anti-idiotypic antibodies to anti-HLA receptors induced by pregnancy Proc Natl Acad Sci USA 1983; 80: 830.
13. Grosse-Wilde H, Blasczyk R, Westhoff U. Soluble HLA class I and class II concentrations in commercial immunoglobulin preparations. Tissue Antigens 1991; 39: 74.
14. Toungouz M, Denys C, De Groote D, Dupont E. In vitro inhibition of tumour necrosis factor-α and interleukin-6 production by intravenous immunoglobulins. Br J Haematol 1995; 89: 698.
15. Caruso A, Bonfanti C, Colombrita D, et al. Natural antibodies to IFN-γ in man and their increase during viral infection. J Immunol 1990; 144: 685.
16. Ross C, Svenson M, Hansen MB, Vejlsgaard GL, Bendtzen K. High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG. J Clin Invest 1995; 95: 1974.
17. Ross C, Hansen MB, Schyberg T, Berg K. Autoantibodies to crude human leucocyte interferon (IFN), native human IFN, recombinant human IFN-alpha 2b and human IFN-gamma in healthy blood donors. Clin Exp Immunol 1990; 82: 57.
18. Turano A, Balsari A, Viani E, et al. Natural human antibodies to γ interferon interfere with the immunomodulating activity of the lymphokine. Proc Natl Acad Sci USA 1992; 89: 4447.
19. Farrar MA, Schreiber RD. The molecular cell biology of interferon-γ and its receptor. Annu Rev Immunol 1993; 11: 571.
20. Novelli F, Giovarelli M, Reber-Liske R, Virgallita G, Garotta G, Forni G. Blockade of physiologically secreted IFN-γ inhibits human T lymphocyte and natural killer cell activation. J Immunol 1991; 147: 1445.
21. Toungouz M, Denys C, Andrien M, De Groote D, Dupont U. Interleukin-12 unmasks HLA class I differences during mixed lymphocyte reaction induced interferon-γ production. Hum Immunol 1995; 44: 145.
22. Shalaby MR, Espevik T, Rice GC, et al. The involvement of the human tumor necrosis factors-α and -β in the mixed lymphocyte reaction. J Immunol 1988; 141: 499.
23. Siegel JP. Effects of interferon-γ on the activation of human T lymphocytes. Cell Immunol 1988; 111: 461.
24. Danzer SG, Kirchner H, Rink L. Cytokine interactions in human mixed lymphocyte culture. Transplantation 1994; 57: 1638.
25. Ochs HD, Morell A, Skvaril F, Fischer SH, Wedgwood RJ. Survival of IgG subclasses following administration of intravenous immunoglobulin in patients with primary immunodeficiency diseases. In: Morell A, Nydegger UE, eds. Clinical use of intravenous immunoglobulins. London: Academic Press, 1986: 77.
26. Novelli F, Giovarelli M, Reber-Liske R, Virgallita G, Garotta G, Forni G. Blockade of physiologically secreted IFN-γ inhibits human T lymphocyte and natural killer cell activation. J Immunol 1991; 147: 1445.
27. Svenson M, Bagge MB, Bendtzen K. Binding of cytokines to pharmaceutically prepared human immunoglobulin. J Clin Invest 1993; 92: 2533.
28. Leusch HG, Sitzler G, Markos-Pusztai S. Failure to demonstrate TNFα-specific autoantibodies in human sera by ELISA and Western blot. J Immunol Methods 1991; 139: 145.
29. Glotz D, Haymann P, Niaudet P, Lang P, Druet P, Bariety J. Successful kidney transplantation of immunized patients after desensitization with normal human polyclonal immunoglobulins. Transplant Proc 1995; 27: 1038.
30. Niederwieser D, Herold M, Woloszczuk W, et al. Endogenous IFN-gamma during human bone marrow transplantation. Transplantation 1990; 50: 625.
31. Holler E, Kolb HJ, Möller A, et al. Increased serum levels of tumor necrosis factor α precede major complications of bone marrow transplantation. Blood 1990; 75: 1011.
32. Noronha IL, Eberlein-Gonska M, Hartley B, Stephens S, Cameron JS, Waldherr R. In situ expression of tumor necrosis factor-alpha, interferon-gamma and interleukin-2 receptors in renal allograft biopsies. Transplantation 1992; 54: 1017.
33. Piguet P-F, Grau GE, Allet B, Vassali P. Tumor necrosis factor/ cachectin is an effector of skin and gut lesions of the acute phase of graft-vs-host disease. J Exp Med 1987; 166: 1280.
34. Mowat AM. Antibodies to IFN-γ prevent immunologically mediated intestinal damage in murine graft-versus-host reaction. Immunology 1989; 68: 18.
35. Billingham RE. The biology of graft-versus-host reaction. Harvey Lect 1966; 62: 21.
36. Maraskovsky E, Chen W-F, Shortman K. IL-2 and IFN-γ are two necessary lymphokines in the development of cytolytic T cells. J Immunol 1989; 143: 1210.